CN1145238A - Wuling C-hepatitis powder - Google Patents
Wuling C-hepatitis powder Download PDFInfo
- Publication number
- CN1145238A CN1145238A CN 95115623 CN95115623A CN1145238A CN 1145238 A CN1145238 A CN 1145238A CN 95115623 CN95115623 CN 95115623 CN 95115623 A CN95115623 A CN 95115623A CN 1145238 A CN1145238 A CN 1145238A
- Authority
- CN
- China
- Prior art keywords
- radix
- hepatitis
- powder
- wuling
- poria
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
A Chinese patent medicine for resisting hepatitis C virus, making the virus antibody change to negative (66.7%) and increasing immunity with effective rate of 93.3% is prepared from 12 Chinese-medicinal materials such as schisandra fruit, tuckahoe, oriental wormwood, bupleurum root, liquorice root, etc.
Description
Wuling C-hepatitis powder belongs to Chinese patent medicine.
The Chinese patent medicine of treatment hepatitis belongs to symptomatic treatment at present, and its clinical effectiveness is not good, and the antiviral drugs of high specificity, the function of do not possess the protection liver function again, regulating immunity of organism, transaminase lowering.
The objective of the invention is to develop a kind of have anti-hepatitis C virus RNA viruses, raising hepatitis C negative conversion rate, the liver protecting function, mould, the enhancing human body immunity function of recovery commentaries on classics ammonia, clinical Chinese patent medicine with Wuling C-hepatitis powder of Comprehensive Treatment hepatitis C.
The present invention is made up of Fructus Schisandrae Chinensis, Poria, Radix Ophiopogonis, Herba Artemisiae Scopariae, Radix Bupleuri, Radix Glycyrrhizae, Spica Prunellae, Radix Gentianae, the Radix Paeoniae Alba, Radix Salviae Miltiorrhizae, charred Radix Et Rhizoma Rhei, Herba Hedyotidis Diffusae.They respectively account for by weight percentage: Fructus Schisandrae Chinensis 6～7, Poria 6～7, Radix Ophiopogonis 9.5～10.5, Herba Artemisiae Scopariae 6～7, Radix Bupleuri 6～7, Radix Glycyrrhizae 9.5～10.5, Spica Prunellae 9.5～11.5, Radix Gentianae 6～7, the Radix Paeoniae Alba 12～13, Radix Salviae Miltiorrhizae 7.5～8.5, charred Radix Et Rhizoma Rhei 1.5～2.5, Herba Hedyotidis Diffusae 14.5～15.5.
Chinese patent medicine of the present invention has the pharmacology of anti-hepatitis C virus RNA, the effect that hepatitis C virus antibody is turned out cloudy.It also has the effect of falling mould, raise immunity, dispersing the stagnated live-QI to relieve the stagnation of QI.The effective percentage of taking this medicine treatment hepatitis C is 93.3%, and negative conversion rate is 66.7%, the advantage of non-relapse after healing.
Embodiment: select Fructus Schisandrae Chinensis 6.5, Poria 6.5, Radix Ophiopogonis 10, Herba Artemisiae Scopariae 6.5, Radix Bupleuri 6.5, Radix Glycyrrhizae 10, Spica Prunellae 10, Radix Gentianae 6.5, the Radix Paeoniae Alba 12.5, Radix Salviae Miltiorrhizae 8, charred Radix Et Rhizoma Rhei 2, Herba Hedyotidis Diffusae 15 by weight percentage.Above 12 flavor medicated powder are broken, cross sieve No. 5, again through cobalt
60Sterilize and got final product packing in 30 minutes.
Claims (1)
1, Wuling C-hepatitis powder, it is characterized in that it is made up of Fructus Schisandrae Chinensis, Poria, Radix Ophiopogonis, Herba Artemisiae Scopariae, Radix Bupleuri, Radix Glycyrrhizae, Spica Prunellae, Radix Gentianae, the Radix Paeoniae Alba, Radix Salviae Miltiorrhizae, charred Radix Et Rhizoma Rhei, Herba Hedyotidis Diffusae, they respectively account for by weight percentage: Fructus Schisandrae Chinensis 6～7, Poria 6～7, Radix Ophiopogonis 9.5～10.5, Herba Artemisiae Scopariae 6～7, Radix Bupleuri 6～7, Spica Prunellae 9.5～10.5, Radix Gentianae 6～7, the Radix Paeoniae Alba 12～13, Radix Salviae Miltiorrhizae 7.5～8.5, charred Radix Et Rhizoma Rhei 1.5～2.5, Herba Hedyotidis Diffusae 1.45～15.5.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN95115623A CN1053825C (en) | 1995-09-15 | 1995-09-15 | Wuling C-hepatitis powder |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN95115623A CN1053825C (en) | 1995-09-15 | 1995-09-15 | Wuling C-hepatitis powder |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1145238A true CN1145238A (en) | 1997-03-19 |
| CN1053825C CN1053825C (en) | 2000-06-28 |
Family
ID=5080572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN95115623A Expired - Fee Related CN1053825C (en) | 1995-09-15 | 1995-09-15 | Wuling C-hepatitis powder |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1053825C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005079823A1 (en) * | 2004-02-19 | 2005-09-01 | Phynova Limited | Plant-based medicament for the treatment of hepatitis c |
| WO2007020382A3 (en) * | 2005-08-12 | 2007-05-31 | Phynova Ltd | Plant-based medicament for the treatment of liver disease |
| CN1899370B (en) * | 2006-07-01 | 2010-05-26 | 邓德刚 | Compound calyx melo extract tablet |
-
1995
- 1995-09-15 CN CN95115623A patent/CN1053825C/en not_active Expired - Fee Related
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005079823A1 (en) * | 2004-02-19 | 2005-09-01 | Phynova Limited | Plant-based medicament for the treatment of hepatitis c |
| JP2007523144A (en) * | 2004-02-19 | 2007-08-16 | ファイノバ・リミテッド | Botanical medicine for treating hepatitis C |
| EA014234B1 (en) * | 2004-02-19 | 2010-10-29 | Финова Лимитед | Composition for the treatment of hepatitis c or dietary supplement for prevention or alleviation hepatitis c symptoms |
| WO2007020382A3 (en) * | 2005-08-12 | 2007-05-31 | Phynova Ltd | Plant-based medicament for the treatment of liver disease |
| CN1899370B (en) * | 2006-07-01 | 2010-05-26 | 邓德刚 | Compound calyx melo extract tablet |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1053825C (en) | 2000-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101152539A (en) | Traditional Chinese medicine for treating acute icteric hepatitis | |
| CN1186687A (en) | Cancer preventing curing medicine series and its preparation | |
| CN1053825C (en) | Wuling C-hepatitis powder | |
| CN101167932A (en) | Traditional Chinese medicine for treating chronic hepatitis B | |
| CN102988886A (en) | Chinese medicament for treating obesity | |
| CN101167969A (en) | Traditional Chinese medicine for treating meniere's syndrome | |
| CN1385191A (en) | Medicine for treating liver disease | |
| CN102813733A (en) | Herb tea capable of resisting cancer, preventing diabetes mellitus and enhancing immunity | |
| CN1045387C (en) | "Sancao" medicine powder for hepatitis B | |
| CN1090183A (en) | Artemisia scoparia and ginseng pellet for mourishing liver and method for production thereof | |
| CN1224413C (en) | Chinese medicine granule preparation for curing stomatocace | |
| CN1053815C (en) | Cundanzhengxin powder for viral myocarditis | |
| CN1052913C (en) | Classified liver treating agent and it prepn. method | |
| CN1223361C (en) | Decoction for positive reaction of hepatitis B transformation to negative | |
| CN1086141C (en) | Medicine for treating early-stage hepatocirrhosis and its preparation | |
| CN1130529A (en) | Aizikangfuning-Chinese patent drug for treating AIDS and preparing process thereof | |
| CN101991762A (en) | Traditional Chinese medicine for treating refractory asthma and preparation method thereof | |
| CN1136896C (en) | Live-nourishing 'yanggan' pill | |
| CN1102591A (en) | Three-seedling compound mixture and formula thereof | |
| CN1058622C (en) | Rehabilitation powder for hepatitis B | |
| CN1173352A (en) | Kechuan'an | |
| CN101352496A (en) | Traditional Chinese medicine for treating hepatitis | |
| CN1634471A (en) | Chinese traditional medicine for treating cardiopathy | |
| CN1824168A (en) | Sancaoyigan powdar preparation for treating hepatitis B | |
| CN1150929C (en) | Malian liver-clearing electuary |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |